| Hyperhomocysteinemia as a risk factor for deep-vein thrombosis M Den Heijer, T Koster, HJ Blom, GMJ Bos, E Briët, PH Reitsma, ... New England journal of medicine 334 (12), 759-762, 1996 | 1505 | 1996 |
| Bortezomib induction and maintenance treatment in patients with newly diagnosed multiple myeloma: results of the randomized phase III HOVON-65/GMMG-HD4 trial P Sonneveld, IGH Schmidt-Wolf, B van der Holt, L El Jarari, U Bertsch, ... Journal of clinical oncology 30 (24), 2946-2955, 2012 | 1011 | 2012 |
| The incidence of deep venous thrombosis and pulmonary embolism among patients with inflammatory bowel disease: a population-based cohort study CN Bernstein, JF Blanchard, DS Houston, A Wajda Thrombosis and haemostasis 85 (03), 430-434, 2001 | 731 | 2001 |
| Hyperhomocysteinemia and venous thrombosis: a meta-analysis M Den Heijer, FR Rosendaal, HJ Blom, WBJ Gerrits, GMJ Bos Thrombosis and haemostasis 80 (12), 874-877, 1998 | 557 | 1998 |
| Is hyperhomocysteinaemia a risk factor for recurrent venous thrombosis? M den Heijer, WBJ Gerrits, HL Haak, PW Wijermans, GMJ Bos, HJ Blom, ... The Lancet 345 (8954), 882-885, 1995 | 529 | 1995 |
| A randomized phase 3 study on the effect of thalidomide combined with adriamycin, dexamethasone, and high-dose melphalan, followed by thalidomide maintenance in patients with … HM Lokhorst, B van der Holt, S Zweegman, E Vellenga, S Croockewit, ... Blood, The Journal of the American Society of Hematology 115 (6), 1113-1120, 2010 | 335 | 2010 |
| Homocysteine lowering by B vitamins and the secondary prevention of deep vein thrombosis and pulmonary embolism: a randomized, placebo-controlled, double-blind trial M Den Heijer, HPJ Willems, HJ Blom, WBJ Gerrits, M Cattaneo, ... Blood 109 (1), 139-144, 2007 | 330 | 2007 |
| Autologous haematopoietic stem-cell transplantation versus bortezomib–melphalan–prednisone, with or without bortezomib–lenalidomide–dexamethasone consolidation therapy, and … M Cavo, F Gay, M Beksac, L Pantani, MT Petrucci, MA Dimopoulos, ... The Lancet Haematology 7 (6), e456-e468, 2020 | 320 | 2020 |
| Vitamin supplementation reduces blood homocysteine levels: a controlled trial in patients with venous thrombosis and healthy volunteers M Den Heijer, IA Brouwer, GMJ Bos, HJ Blom, NMJ Van Der Put, ... Arteriosclerosis, thrombosis, and vascular biology 18 (3), 356-361, 1998 | 248 | 1998 |
| Visualising the invisible: a network approach to reveal the informal social side of student learning J Hommes, B Rienties, W de Grave, G Bos, L Schuwirth, A Scherpbier Advances in Health Sciences Education 17, 743-757, 2012 | 231 | 2012 |
| Phenotyping the clotting system HC Hemker, S Béguin Thrombosis and haemostasis 84 (11), 747-751, 2000 | 221 | 2000 |
| Recurrent venous thrombosis and markers of inflammation BE Van Aken, M Den Heijer, GMJ Bos, SJH Van Deventer, PH Reitsma Thrombosis and haemostasis 83 (04), 536-539, 2000 | 191 | 2000 |
| Bisphosphonates in multiple myeloma. B Djulbegovic, K Wheatley, J Ross, O Clark, G Bos, H Goldschmidt, ... The Cochrane database of systematic reviews, CD003188-CD003188, 2001 | 185 | 2001 |
| Thalidomide in induction treatment increases the very good partial response rate before and after high-dose therapy in previously untreated multiple myeloma HM Lokhorst, I Schmidt-Wolf, PS Van Der Holt, H Martin, R Barge, ... Haematologica 93 (1), 124-127, 2008 | 182 | 2008 |
| Influence of vitamin C on lymphocytes: an overview GNY Van Gorkom, RGJ Klein Wolterink, CHMJ Van Elssen, L Wieten, ... Antioxidants 7 (3), 41, 2018 | 167 | 2018 |
| Successful Transfer of Umbilical Cord Blood CD34+ Hematopoietic Stem and Progenitor-derived NK Cells in Older Acute Myeloid Leukemia Patients H Dolstra, MWH Roeven, J Spanholtz, BN Hangalapura, M Tordoir, ... Clinical Cancer Research 23 (15), 4107-4118, 2017 | 165 | 2017 |
| Hypoxia induced impairment of NK cell cytotoxicity against multiple myeloma can be overcome by IL-2 activation of the NK cells S Sarkar, WTV Germeraad, KMA Rouschop, EMP Steeghs, M Gelder, ... PloS one 8 (5), e64835, 2013 | 164 | 2013 |
| Chimeric antigen receptor natural killer (CAR-NK) cell design and engineering for cancer therapy Y Gong, RGJ Klein Wolterink, J Wang, GMJ Bos, WTV Germeraad Journal of hematology & oncology 14 (1), 73, 2021 | 160 | 2021 |
| HOVON-65/GMMG-HD4 randomized phase III trial comparing bortezomib, doxorubicin, dexamethasone (PAD) vs VAD followed by high-dose melphalan (HDM) and maintenance with bortezomib … P Sonneveld, I Schmidt-Wolf, B van der Holt, L Jarari, U Bertsch, ... Blood, The Journal of the American Society of Hematology 116 (21), 40-40, 2010 | 152 | 2010 |
| Bortezomib before and after autologous stem cell transplantation overcomes the negative prognostic impact of renal impairment in newly diagnosed multiple myeloma: a subgroup … C Scheid, P Sonneveld, IGH Schmidt-Wolf, B van der Holt, L el Jarari, ... haematologica 99 (1), 148, 2014 | 149 | 2014 |
